Propanc Biopharma PPCB 深 沪
已收盘 10-30 16:00:00 美东时间
1.84
-0.270
-12.80%
华盛通- 最 高2.13
- 今 开1.91
- 成交量 6.56万股
- 最 低 1.79
- 昨 收 2.11
- 总市值 190.09万
- 52周最高 225.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.79
- 委 比 95.55%
- 总股本 103.31万
- 历史最高 2340.00
- 量 比 0.61
- 振 幅 16.11%
- 历史最低 1.79
- 每 手 1
- 风险率 75.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Propanc Biopharma收跌18.21%，成交额26.49万美元
10月27日，Propanc Biopharma（PPCB）收跌18.21%，报2.29美元，成交额26.49万美元，市值2365.82万美元。 行情数据 •...
10-27 07:44
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Propanc Biopharma announced new preclinical data supporting PRP's potential to address chemotherapy resistance in pancreatic cancer. PRP, a proprietary enzyme formulation, demonstrated anti-tumor activity, EMT reversal, and chemosensitization in preclinical models. Key findings include reduced cancer cell proliferation, inhibited metastasis, and enhanced response to chemotherapy. PRP's mechanism targets cancer stem cells and fibrosis, complementi...
10-26 12:30
Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company’...
10-22 20:32
Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical research from an academic–industry collaboration from the Universiti...
10-16 20:45
Propanc Biopharma Q4 EPS $(0.10)
Propanc Biopharma (NASDAQ:PPCB) reported quarterly losses of $(0.10) per share.
09-29 21:46
Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of lead candidate PRP against recently reported clinical datase...
09-22 20:34
Pre-Bell Movers | WHLR Rises by 125.9%; Here Are 20 Stocks Moving Premarket (Aug 28)
US stock futures mixed as markets await Fed Chair Warsh’s Jackson Hole speech, with big moves in premarket trading driven by earnings, guidance, and M&A news.
08-28 16:29
Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.
Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.
08-27 20:43
Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for PRP showing >90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models.
Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for PRP showing >90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models.
08-07 01:19
Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell Factories
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Gra...
07-21 20:33
